The DOI matches its Crossref record.
Anti-human leukocyte antigen antibodies and preemptive antibody-directed therapy after lung transplantation
Open accessAbstract
Background Because the development of donor-specific anti-HLA antibodies (DSA) after lung transplantation has been associated with acute and chronic rejection we implemented a clinical protocol to screen all recipients for DSA after transplantation and preemptively treat those who develop DSA with rituximab and intravenous immune globulin (IVIG) or IVIG alone. Methods We conducted a prospective observational study of this protocol and used the LABScreen® Single Antigen assay to detect DSA after transplantation. We compared the incidence of acute rejection, lymphocytic bronchiolitis, and bronchiolitis obliterans syndrome (BOS) between those who developed DSA and those who did not using Cox proportional hazards models and compared freedom from BOS and survival between those who had persistent DSA and those who had successful depletion of DSA using the Kaplan-Meier method. Results Among 116 recipients screened, 65 developed DSA during the study period. Those who developed DSA and received antibody-directed therapy had a similar incidence of acute rejection, lymphocytic bronchiolitis, and BOS as those who did not develop DSA. Furthermore, recipients who had successful depletion of DSA had greater freedom from BOS and better survival than those who had persistent DSA. Finally, those treated for DSA had a similar incidence of infectious complications as those who did not develop DSA. Conclusions The development of DSA is surprisingly common after lung transplantation. Antibody-directed therapy may reduce the risk of rejection associated with DSA, but a randomized controlled trial is necessary to critically evaluate the efficacy of this treatment protocol.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Verleden, G. M., Glanville, A. R., Lease, E. D., Fisher, A. J., Calabrese, F., Corris, P. A., Ensor, C. R., Gottlieb, J., Hachem, R. R., Lama, V., et al. (2019) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2019.03.009 · Cited by 952
Self-citationTait, B. D., Süsal, C., Gebel, H. M., Nickerson, P. W., Zachary, A. A., Claas, F. H. J., Reed, E. F., Bray, R. A., Campbell, P., Chapman, J. R., et al. (2013) · Transplantation · doi:10.1097/tp.0b013e31827a19cc · Cited by 787
Self-citationUpdate on the use of immunoglobulin in human disease: A review of evidence
Perez, E. E., Orange, J. S., Bonilla, F., Chinen, J., Chinn, I. K., Dorsey, M., El-Gamal, Y., Harville, T. O., Hossny, E., Mazer, B., et al. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.09.023 · Cited by 666
Levine, D. J., Glanville, A. R., Aboyoun, C., Belperio, J., Benden, C., Berry, G. J., Hachem, R., Hayes, D., Neil, D., Reinsmoen, N. L., et al. (2016) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2016.01.1223 · Cited by 488
Self-citationIncidence and Impact of De Novo Donor-Specific Alloantibody in Primary Renal Allografts
Everly, M. J., Rebellato, L. M., Haisch, C. E., Ozawa, M., Parker, K., Briley, K. P., Catrou, P. G., Bolin, P., Kendrick, W. T., Kendrick, S. A., et al. (2013) · Transplantation · doi:10.1097/tp.0b013e31827d62e3 · Cited by 385
Metadata
- Authors
- Hachem, R. R., Yusen, R. D., Meyers, B. F., Aloush, A. A., Mohanakumar, T., Patterson, G. A., & Trulock, E. P.
- Venue
- The Journal of Heart and Lung Transplantation
- Publisher
- Elsevier BV
- Published
- 2010-09
- Volume
- 29
- Issue
- 9
- Pages
- 973-980
- ISSN
- 1053-2498 (ISSN-L)
- OpenAlex
- W2075033611
- Cited by
- 235
- References
- 0
- FWCI
- 16.15
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anti-human leukocyte antigen antibodies and preemptive antibody-directed therapy after lung transplantation. https://app.cochat.ai/papers/10.1016/j.healun.2010.05.006
- The paper
- Hachem, R. R., Yusen, R. D., Meyers, B. F., Aloush, A. A., Mohanakumar, T., Patterson, G. A., & Trulock, E. P. (2010). Anti-human leukocyte antigen antibodies and preemptive antibody-directed therapy after lung transplantation. The Journal of Heart and Lung Transplantation. https://doi.org/10.1016/j.healun.2010.05.006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.